thermogenesis holdings, inc. develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (car)-t and other cell-based therapies. it markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed car-txpress platform, which streamlines the manufacturing process for the emerging car-t immunotherapy market. the company operates through two segments, device and clinical development. it manufactures and markets products for clinical bio-banking applications, including axp automated cell separation system, an automated cell separation system for isolating and retrieving stem and progenitor cells from umbilical cord blood; and bioarchive automated cryopreservation system, an automated, robotic, liquid nitrogen controlled-rate-freezing, and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical appli
Company profile
Ticker
THMO
Exchange
Website
CEO
Xiaochun Xu
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CESCA THERAPEUTICS INC., THERM0GENESIS CORP, THERMOGENESIS CORP
SEC CIK
Corporate docs
Subsidiaries
ThermoGenesis Corp. • Wholly-owned by ThermoGenesis Holdings, Inc. • CARTXpress Bio Inc. ...
IRS number
943018487
THMO stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
29 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
ThermoGenesis Holdings Announces Second Quarter 2023 Financial Results and Provides Corporate Update
10 Aug 23
8-K
Entry into a Material Definitive Agreement
3 Aug 23
8-K
Departure of Directors or Certain Officers
19 Jul 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
ThermoGenesis Holdings Announces First Quarter 2023 Financial Results and Provides Corporate Update
15 May 23
EFFECT
Notice of effectiveness
2 May 23
CORRESP
Correspondence with SEC
27 Apr 23
UPLOAD
Letter from SEC
25 Apr 23
Transcripts
THMO
Earnings call transcript
2023 Q1
15 May 23
THMO
Earnings call transcript
2022 Q4
30 Mar 23
THMO
Earnings call transcript
2022 Q3
12 Nov 22
THMO
Earnings call transcript
2022 Q2
13 Aug 22
THMO
Earnings call transcript
2022 Q1
19 May 22
THMO
Earnings call transcript
2021 Q4
28 Mar 22
THMO
Earnings call transcript
2021 Q3
13 Nov 21
THMO
Earnings call transcript
2021 Q2
13 Aug 21
THMO
Earnings call transcript
2021 Q1
13 May 21
THMO
Earnings call transcript
2020 Q4
18 Mar 21
Latest ownership filings
SC 13D/A
Boyalife Group, Inc.
14 Aug 23
3
James Xu
24 Jul 23
3
Biao Xi
24 Jul 23
SC 13D/A
Boyalife Group, Inc.
11 Apr 23
SC 13D/A
Xu Xiaochun
9 Mar 23
SC 13D/A
FOLEY & LARDNER/ FA
16 Feb 23
SC 13D/A
Boyalife Group, Inc.
9 Nov 22
SC 13D/A
Boyalife Asset Holding II, Inc.
5 Aug 22
SC 13D/A
Boyalife Asset Holding II, Inc.
12 Jul 22
4
Xiaochun Xu
30 Jun 22
Financial summary
| Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 4.45 mm | 4.45 mm | 4.45 mm | 4.45 mm | 4.45 mm | 4.45 mm |
| Cash burn (monthly) | 468.00 k | (no burn) | 576.67 k | 526.42 k | 270.67 k | 300.75 k |
| Cash used (since last report) | 1.35 mm | n/a | 1.66 mm | 1.52 mm | 780.09 k | 866.79 k |
| Cash remaining | 3.10 mm | n/a | 2.79 mm | 2.93 mm | 3.67 mm | 3.58 mm |
| Runway (months of cash) | 6.6 | n/a | 4.8 | 5.6 | 13.6 | 11.9 |
Institutional ownership, Q2 2023
| 13F holders | Current |
|---|---|
| Total holders | 18 |
| Opened positions | 2 |
| Closed positions | 8 |
| Increased positions | 4 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 919.13 mm |
| Total shares | 58.47 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Boyalife Asset Holding II | 49.80 mm | $10.57 mm |
| Boyalife | 3.04 mm | $13.57 mm |
| Foley & LARDNER/ Fa | 2.76 mm | $10.14 mm |
| Xu Xiaochun | 2.76 mm | $10.14 mm |
| Raymond James & Associates | 50.00 k | $64.01 mm |
| Vanguard | 35.42 k | $45.34 mm |
| Citadel Advisors | 13.42 k | $16.78 mm |
| MS Morgan Stanley | 9.29 k | $11.90 mm |
| Tower Research Capital | 5.76 k | $7.37 mm |
| BLK Blackrock | 1.49 k | $1.91 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 28 Jun 22 | Xu Xiaochun | Common Stock | Conversion | Acquire C | Yes | No | 0.2843 | 10,552,234 | 3.00 mm | 12,281,091 |
| 28 Jun 22 | Xu Xiaochun | Second Amended and Restated Convertible Note Common Stock | Conversion | Dispose C | Yes | No | 0.2843 | - | 3.00 mm | - |
News
HC Wainwright & Co. Reiterates Buy on ThermoGenesis Holdings, Maintains $5 Price Target
11 Aug 23
ThermoGenesis Holdings Q2 EPS $(0.91) Up From $(9.00) YoY, Sales $2.27M Down From $3.03M YoY
10 Aug 23
Earnings Scheduled For August 10, 2023
10 Aug 23
12 Health Care Stocks Moving In Tuesday's After-Market Session
25 Jul 23
Press releases
ThermoGenesis Holdings to Present at the H.C. Wainwright 25th Annual Global Investment Conference
6 Sep 23
ThermoGenesis Holdings Announces Second Quarter 2023 Financial Results and Provides Corporate Update
10 Aug 23
ThermoGenesis Holdings to Announce Financial Results for the Second Quarter ended June 30, 2023 and Provide a Corporate Strategic Update
8 Aug 23
ThermoGenesis Expands Board of Directors with the Appointments of Dr. Biao Xi and Dr. James Xu
17 Jul 23